Astroblastoma

Summary

Astroblastoma (MONDO:0016707) is a disease and 1 clinical trial. A subtype of glioma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Prevalence: <1 / 1 000 000 (Europe) [Orphanet-validated]
• Clinical trials: 1

Clinical features

Epidemiology

Prevalence records

1 prevalence record(s), Orphanet:

Type	Class	Value	Geography	Validation
Annual incidence	<1 / 1 000 000	0.02	Europe	Validated

Identifiers

Disease identifiers

Field	Value
Canonical name	astroblastoma
Mondo ID	MONDO:0016707
Orphanet	251679
DOID	DOID:7305
ICD-11	2011571705, 96344074
NCIT	C4324
UMLS	C0334587
MedGen	90811
GARD	0010635
Is cancer (heuristic)	no

Also known as: AstB · astroblastoma · astroblastoma (morphologic abnormality) · cerebral astroblastoma

Disease family

This is a subtype of glioma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › nervous system neoplasm › neuroepithelial neoplasm › glioma › astroblastoma

Related subtypes (8): nerve sheath neoplasm, ependymal tumor, mixed glioma, optic pathway glioma, astrocytic tumor, low grade glioma, malignant glioma, diffuse glioma, H3 G34 mutant

Subtypes (1): astroblastoma, MN1-altered

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 1.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05697874	Not specified	RECRUITING	International Rare Brain Tumor Registry